Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Dapagliflozin (Farxiga) and finerenone (Kerendia) are both oral medications used to help protect your kidneys if you have chronic kidney disease (CKD) caused by Type 2 diabetes. However, they belong to different medication classes and work in different ways. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps remove extra sugar and sodium through urine, while finerenone is a mineralocorticoid receptor antagonist that blocks hormones which cause inflammation and scarring. Dapagliflozin is also used to lower blood sugar in Type 2 diabetes and reduce heart failure risks, whereas finerenone is specifically for people who have CKD and Type 2 diabetes. Dapagliflozin is available in both brand and generic forms, while finerenone is only available as a brand name medication. Common side effects of dapagliflozin include urinary tract infections, yeast infections, and increased urination, while finerenone can cause high potassium levels and low blood pressure. Dapagliflozin may interact with other diabetes medications and diuretics, whereas finerenone can interact with medications that raise potassium levels.
Farxiga (dapagliflozin)
Kerendia (finerenone)
Farxiga (dapagliflozin)
Kerendia (finerenone)
Summary of Farxiga vs. Kerendia
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)